Stephen Matarese, DO
Pulmonary Disease · Warwick, RINPI 1225016355
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,475 of the $1,813 with a category attached, or 81.4%. 13 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 28.4% of the total. Reporting peaked in 2019 at $1,241 and has fallen 78.0% since, to $273 in 2025.
Across 100 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$516
- GSK$375
- Jazz Pharmaceuticals Inc.$199
- Sanofi$137
- Boehringer Ingelheim$135
- Verona Pharma, Inc.$123
- plus $327 from 7 others
What the payments were for
- Consulting fees$1508%
- Food & beverage$1,47581%
- Education$18810%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 52 | $516 |
| GSK | 24 | $375 |
| Jazz Pharmaceuticals Inc. | 3 | $199 |
| Sanofi | 6 | $137 |
| Boehringer Ingelheim | 4 | $135 |
| Verona Pharma, Inc. | 1 | $123 |
| Harmony Biosciences LLC | 1 | $95 |
| Resmed Corp | 1 | $71 |
| Philips North America LLC | 3 | $66 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| AstraZeneca | 2 | $31 |
| Novartis | 1 | $20 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,813 in reported general payments places this provider in the 65th percentile of 59 pulmonary disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 265 | $187,910 |
| XywavSodium,calcium,mag,pot Oxybate | 21 | $170,698 |
| OfevNintedanib Esylate | 11 | $144,068 |
| OpsumitMacitentan | 11 | $140,974 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $134,332 |
| Dupixent PenDupilumab | 13 | $105,166 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 120 | $63,683 |
| Spiriva RespimatTiotropium Bromide | 97 | $59,976 |
| Breo ElliptaFluticasone/Vilanterol | 145 | $59,029 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 80 | $58,195 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 86 | $56,325 |
| Spiriva HandihalerTiotropium Bromide | 36 | $38,385 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 83 | $23,632 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 43 | $22,979 |
| Incruse ElliptaUmeclidinium Bromide | 62 | $21,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $375 | $348,951672 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $135 | $283,347237 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $31 | $72,440134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 59 pulmonary disease providers in Rhode Island.
Other pulmonary disease in Warwick
- William CorraoWarwick$166K
- Thomas RaimondoWarwick$8K
- Anuradha RamaswamyWarwick$3K
- Elias JabbourWarwick$2K
- Khalid AlhouraniWarwick$2K
- Ashish ThakkarWarwick$1K
- Neil LaboveWarwick$350
- Gerald WeinhouseWarwick$15
- Michael StanchinaEast Greenwich$219K
- Corey VentetuoloRiverside$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.